|Bid||0.00 x 4000|
|Ask||0.00 x 900|
|Day's Range||72.91 - 73.52|
|52 Week Range||61.05 - 78.38|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||24.65|
|Earnings Date||Apr 24, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||0.76 (1.05%)|
|1y Target Est||78.53|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! This article is for investors who wouldRead More...
Baxter International Inc. , a leading global medical products company, will present at the Barclays Global Healthcare Conference in Miami, Fla. on March 12, 2019. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 3:20 p.m.
Dan Loeb's Third Point Had a Weak 2018: Will 2019 Be Any Better?(Continued from Prior Part)Third Point’s only new position In Q4 2018, Third Point initiated a new position in Cigna (CI), which is an American healthcare services organization. Hike
@baxter_intl and @NantHealth advance DigitalHealth technology for medical devices in the hospital ICU #CriticalCare #HIMSS19
Baxter International Inc NYSE:BAXView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BAX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $16.62 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. BAX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Baxter International Inc. , a leading global medical products company, will present at the Raymond James 40th Annual Institutional Investors Conference in Orlando, Fla. on Tuesday, March 5, 2019.
ProvideGx, a subsidiary of Charlotte-based Premier Inc., is partnering with Baxter Healthcare Corp. to make generic drugs more readily available.
Abbott or Stryker: Which Is a Better Medtech Bet in This Month?(Continued from Prior Part)High-growth businessesOn its fourth-quarter earnings conference call, Abbott Laboratories (ABT) forecast that its Established Pharmaceuticals segment would
A new venture to supply generic medicines says it will start with a blood-pressure drug that has been hard to get. ProvideGx, the new generic-drug venture, will begin supplying metoprolol in the middle of this month, according to executives at Premier Inc., which unveiled the subsidiary last month. Neither Premier nor Baxter would say how much their metoprolol would be priced, saying they don’t want to disclose the price to competitors.
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Baxter (BAX) delivered earnings and revenue surprises of 6.85% and 1.45%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Deerfield, Illinois-based company said it had profit of 65 cents. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to 78 cents per share. ...
DEERFIELD, Ill.-- -- Fourth-quarter revenue of $2.8 billion increased 2 percent on a reported basis and 5 percent on an operational basis Fourth-quarter GAAP earnings per share of $0.66; adjusted EPS of $0.78 increased 22 percent Full-year revenue of $11.1 billion increased 5 percent on a reported basis and 3 percent on an operational basis Full-year GAAP earnings per share were $2.99; adjusted EPS ...
If you are currently a shareholder in Baxter International Inc. (NYSE:BAX), or considering investing in the stock, you need to examine how the business generates cash, and how it is Read More...
Baxter International, which reported $10.6 billion in sales in 2017, has not disclosed costs nor specific product details related to the acquisition of True Process.
Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.
Baxter International Inc. , a leading global medical products company, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Thursday, February 28, 2019.
Warning! GuruFocus has detected 4 Warning Signs with BAX. Data shows that some investors GuruFocus tracks have also channeled funds into a specific holding that spans an outsized portion of their portfolios. For instance, Buffett has about a quarter of Berkshire Hathaway (BRK-A)(BRK-B)'s portfolio in Apple (AAPL), and Seth Klarman (Trades, Portfolio) has 19% of Baupost Group's portfolio in Twenty-First Century Fox (FOXA), which are discussed here.
Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.